RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL(S):

The goal of the SYMLIN REMS is to mitigate the risk of severe hypoglycemia associated with SYMLIN by:

- informing health care providers about the risk of severe hypoglycemia as SYMLIN is used with insulin and the importance of insulin dose reduction
- informing health care providers of the importance of proper patient selection for treatment with SYMLIN

II. REMS ELEMENTS:

A. Communication Plan

AstraZeneca will implement a communication plan to health care providers to support implementation of this REMS.

1. REMS Communications
   a. REMS Letters

REMS Letters will be sent to a selected group of health care providers and professional societies. The REMS Letter will address the risk of severe hypoglycemia, the importance of insulin dose reduction and proper patient selection. The letter will be distributed within 60 days of approval of the SYMLIN REMS and again one year from the date of initial approval for the SYMLIN REMS. SYMLIN REMS Letter will be distributed via electronic means (email and/or fax) or by mail within one week if no email or fax contact information is available. If the electronic communication is returned due to an invalid email address or
undeliverable for any other reason, the health care providers will receive the letter through mail within 30 days.

A copy or a link to the Prescribing Information and REMS Factsheet will accompany each REMS Letter.

In addition, the REMS Letter, Prescribing Information and REMS Factsheet will also be available on the SYMLIN REMS website [www.symlinrems.com].

i. REMS Letter for Health Care Providers

The intended audience for this REMS Letter for Health Care Providers will be providers who have prescribed SYMLIN and/or have frequently prescribed mealtime insulin within the past 12 months, including physicians, nurse practitioners, and physician assistants.

ii. REMS Letter for Professional Organizations

A REMS Letter for Professional Societies will be distributed by direct mail or electronic delivery within 60 days of the REMS approval date. This communication to professional organizations will include the same information as that contained in the REMS Letter for Health Care Providers. AstraZeneca will request that these organizations disseminate this information to their members. AstraZeneca will communicate the letter to the leadership of the following professional organizations:

- American Association of Clinical Endocrinologists (AACE)
- American College of Endocrinology (ACE)
- American Diabetes Association (ADA)
- The Endocrine Society (Endo)
- National Diabetes Education Program (NDEP)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- American Academy of Family Physicians (AAFP)
- American College of Physicians (ACP)
- National Medical Association (NMA)
- Society of General Internal Medicine (SGIM)
- American Academy of Nurse Practitioners (AANP)
- American Academy of Physician Assistants (AAPA)
- American Association of Diabetes Educators (AADE)
- Endocrine Nurses Society (ENS)
- American Nurses Association (ANA)
- Family Medicine Residency Nurses Association (FMRNA)
- American Pharmacists Association (APhA)
- American Society of Health-System Pharmacists (ASHP)
- National Association of Chain Drug Stores (NACDS)
- National Community Pharmacy Association (NCPA).

The REMS Factsheet and Prescribing Information will be provided in conjunction with the Letter.
The following REMS Correspondences are part of the REMS and are appended.

- REMS Letter for Health Care Providers (print version)
- REMS Letter for Health Care Providers (email version)
- REMS Letter for Professional Societies (print version)
- REMS Letter for Professional Societies (email version)

2. REMS Factsheet

A REMS Factsheet for health care providers will be distributed via non-personal (as an enclosure in the Letters) and personal methods (by field personnel during the first discussion of SYMLIN with health care providers during the 12-months following REMS approval).

The REMS Factsheet for health care providers is part of the REMS and is appended.

3. Scientific Meetings

The SYMLIN Factsheet and the Prescribing Information will be prominently displayed at scientific meetings where AstraZeneca has a presence (e.g., booth) 18 months after approval of the initial REMS.

4. REMS Website

The Symlin REMS Program Website [www.symlinrems.com] will include the option to print the PI, Medication Guide, REMS Letters, and REMS Factsheet. The SYMLIN product website will include a prominent REMS-specific link to SYMLIN REMS Program Website. All website information will be updated within 60 days post approval of the most recent modification. The SYMLIN REMS website is part of the REMS and is appended.

B. Timetable for Submission of Assessments

AstraZeneca will submit REMS Assessments to the FDA at 18 months, 3 years, and 7 years from the date of the REMS approval. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. AstraZeneca will submit each assessment so that it will be received by the FDA on or before the due date.